San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life sciences investors.
May 20, 2026 02:12 PM EDT
FinancingStartups
Exclusive: Another I&I biotech, Gerhart-led cAMPfield, draws top-tier investors in $180M Series A
Kyle LaHucik
Biotech Correspondent
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
Cartesian’s $150M financing; Editas Medicine’s money moves
